Start Your Search
SCLC and early stage NSCLC (ID 62)
- Event: ELCC 2017
- Type: Proffered Paper session
- Presentations: 1
44O - Validation of the prognostic value of 8th edition revisions of the AJCC staging system for non-small cell lung cancer: A SEER database analysis (ID 494)
09:00 - 10:30 | Author(s): O. Abdel-Rahman
The 8[th] edition of the American Joint Committee on Cancer (AJCC) staging system for non-small cell lung cancer (NSCLC) has been released. The current study seeks to validate the prognostic significance of the new system among patients registered within the surveillance, epidemiology and end results (SEER) database.
SEER database (2010-2013) has been accessed through SEER*Stat program and AJCC 8[th] edition stages were reconstructed utilizing the collaborative stage descriptions. Overall and lung cancer-specific survival analyses according to both 7[th] and 8[th] editions were conducted through Kaplan-Meier analysis and multivariate analysis was conducted through a Cox proportional hazard model.
A total of 127096 patients with NSCLC were identified in the period from 2010-2013. For overall survival assessment according to the 8[th] edition, P values for all pair wise comparisons among different stages were significant (<0.0001) except for the comparison between stage IIA and stage IIB (P = 0.102). For lung cancer-specific survival according to the 8[th] edition, P values for all pair wise comparisons among different stages were significant (<0.0001). Among patients with stage I disease, multivariate analysis for factors affecting overall and lung cancer-specific survival among patients with stage I disease was conducted. The following factors were associated with worse overall and lung cancer-specific survival (age ≥ 70 years, more advanced stage, male gender, squamous histology, no surgery and no radiotherapy) (P < 0.0001 for all factors).
This SEER analysis supports the prognostic significance of the added sub-stages described within AJCC 8[th] edition stages I and III. Further work is needed to incorporate molecular markers and personalize the future editions of the AJCC staging system.
Clinical trial identification:
Legal entity responsible for the study:
The author has declared no conflicts of interest.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.